JNJ-78306358, a first-in-class bispecific T cell engaging antibody targeting CD3 and HLA-GNataša Obermajer(Johnson & Johnson (United States)), Sylvie Laquerre(GlaxoSmithKline (United States))iScienceFebruary 4, 202510.1016/j.isci.2025.111876Cited by 5SaveCiteExport RISWatch citationsRelated PapersGSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained <i>In Vivo</i> Pathway Inhibition|Clinical Cancer Research|2011|600Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions|PLoS ONE|2013|216